Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART +0.64%70 Debt-to-EBITDA is 8.72 as of Mar. 2026, which is 49% above its 10-year median of 5.85. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $23.82 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Integra Lifesciences Holdings's Debt-to-EBITDA or its related term are showing as below:
IART'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.96 Med: 5.85 Max: 13.6
Current: -6.96
During the past 13 years, the highest Debt-to-EBITDA Ratio of Integra Lifesciences Holdings was 13.60. The lowest was -6.96. And the median was 5.85.
IART's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs IART: -6.96
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Integra Lifesciences Holdings Debt-to-EBITDA Related Terms
Integra Lifesciences Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IART vs ATEC, AHCO, INSP: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Integra Lifesciences Holdings (IART) has a Debt-to-EBITDA of 8.72 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integra Lifesciences Holdings. This is 49% above median its historical median of 5.85. According to the industry distribution chart, Integra Lifesciences Holdings ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Integra Lifesciences Holdings' Debt-to-EBITDA too high?
Integra Lifesciences Holdings' current Debt-to-EBITDA of 8.72 is 49% above median its 10-year median of 5.85. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Integra Lifesciences Holdings' value of 8.72 is 455.4% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Debt-to-EBITDA compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Integra Lifesciences Holdings' value of 8.72 is 455.4% above this benchmark. While the company's 10-year median is 5.85 vs. the industry median of 1.57, Integra Lifesciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current Debt-to-EBITDA of 8.72 is 455.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integra Lifesciences Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current Debt-to-EBITDA is 8.72, which is 49% above median its own 10-year median of 5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.82, compared to a current price of $19.01 — trading 20.2% below its estimated fair value. The current Debt-to-EBITDA is 8.72, which is 49% above median its 10-year median of 5.85 and 455.4% above the Medical Devices & Instruments industry median of 1.57. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Debt-to-EBITDA is 8.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $19.01 is trading 20.2% below its estimated GF Value™ of $23.82.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
Debt-to-EBITDA: 8.72 (49% above median its 10-year median of 5.85)
GF Value™: $23.82 vs. price of $19.01 (20.2% below fair value)
Industry Position: 455.4% above the Medical Devices & Instruments median (#999999 of 467)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
